Introduction
Angiotensin II (Ang II) activates phospholipase A 2 (PLA 2 ) to release arachidonate (AA) whose metabolism by cyclooxygenases (COXs) generates prostaglandins (PGs). PGs normally have an antihypertensive action (12). Thus, non-steroidal anti-inflammatory drugs (NSAIDs) exacerbate human hypertension (4) . However, PGH 2 (prostaglandin endoperoxide), thromboxane A 2 (TxA 2 ) generated by thromboxane A 2 synthase (TxA 2 -S) and isoprostanes (Iso) generated by the interaction of superoxide onion (O 2 .- ) with AA (29) , act on TP-Rs that can vasoconstrict blood vessels and the kidney (21, 44) , activate the renal tubuloglomerular feedback (TGF) responses (39, 40) , potentiate central actions of Ang II on the sympathetic nervous system (SNS), vasopressin release and drinking (5, 18, 45) and enhance renal NaCl reabsorption (41) . Activation of TP-Rs has salt retaining and other pro-hypertensive actions (37) .
Unlike in essential hypertension, NSAIDs such as aspirin or indomethacin reduce BP in human renovascular hypertension (10) and 2K,1C hypertension in the rat (32) , suggesting a potentially important role for vasoconstrictor PGs in these conditions.
The relative roles of COX-1 versus -2 products in Ang II dependent hypertension is controversial. Thus, during short term Ang II infusion in the mouse, blockade, or genetic deletion, of COX-1, but not -2, moderates the hypertension and renal medullary vasoconstriction (28) . In contrast, prolonged administration of a COX-2 antagonist moderates hypertension in a rat aortic coarctation model of renovascular hypertension (36) and in a prior study in early 2K,1C hypertension in the rat (26) whereas a COX-1 antagonist was not effective (19) . This may relate to a reduction in plasma renin activity (PRA) accompanying prolonged COX-2 blockade reported in some (26, 36) but not all (6) studies on 2K,1C rats. The present studies were undertaken in the early (3 weeks), Ang II-dependent phase of 2K,1C Goldblatt hypertension in the anesthetized rat. They were designed to test the hypothesis that Ang II acts on type 1 or 2 receptors to generate products of COX-1 or -2 or that activate TP-R to maintain hypertension. The first aim was to contrast the generation of renin, vasoconstrictor PGs, and markers of oxidative stress in sham-operated and 2K,1C hypertensive rats. The second aim was to test the acute BP responses to graded doses, or short infusions, of drugs that inhibit the generation of Ang II by the angiotensin converting enzyme (ACE), PGs by COX-1 or -2, or that block AT 1 -R, AT 2 -R or TP-R to assess the contributions of these pathways to the maintenance of hypertension.
Studies were performed after acute drug administration to minimize the effects of renin secretion. ; ACE inhibitor; n=9).
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The MAP was found to fall to a nadir within 20 min of the injection of the ACEI.
Therefore, data are presented as changes in MAP at this time after which rats received the next bolus dose of the test agent.
Another two groups of rats were prepared as above and given a vehicle (n=9), or a supramaximal dose of benazeprilat (100 mg·kg -1 iv; n=8). Urine was collected from both kidneys via a cannula in the bladder for 45 minutes after the vehicle or ACEI was administered for analysis of TxB 2 .
Series III tested the hypothesis that the maintenance of hypertension depends on the generation of COX-1 or -2 products. Groups of 2K,1C anesthetized rats received graded iv injection of: Additional rats (n=3) were studied using the Na 2 CO 3 solution required to solubilize the indomethacin (42) as a further vehicle control group. This small quantity of Na 2 CO 3 did not produce different changes in BP than the saline vehicle (data not presented).
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Group of 2K,1C rats received a bolus followed by a constant iv infusion over 150 min of:
• These doses of losartan and PD-123,319 were selected from studies of Ang II-infused rats (20, 40) .
Bolus injections were given over one minute. The mean arterial pressure (MAP) was recorded as a maximum reduction within 20 min which encompassed the full early effects for bolus injections when assessed in pilot studies over 30 min periods. All groups had similar starting values for MAP. Therefore, data are presented as changes in MAP from baseline.
Series V tested the hypothesis that the reductions in MAP seen with SQ-29,548 and SC-560 (but not with valdecoxib) could be ascribed to reductions in plasma renin activity (PRA) or TxA 2 generation in the post-clipped kidneys. Groups of 2K,1C rats were prepared as in series III and IV and given vehicle, SQ-29,548, SC-560 or valdecoxib. Thereafter, blood was drawn for PRA, and the post-clipped kidney was removed and frozen at -80˚C prior to extraction and assay for TxB 2 (39).
24-hour urine collections:
A 24-hour urine was collected from rats of series I into containers with indomethacin and antibiotics to prevent ex vivo COX metabolism or bacterial overgrowth (2, 39) . It was filtered, centrifuged and the supernatant frozen at −70 o C until analyzed. Plasma for malondialdehyde (MDA) was measured as described previously (2) (Oxi-Tek, Zeptometrix Corp., Buffalo, NY).
Blood for plasma renin activity (PRA) was taken into cooled, EDTA-containing tubes and the plasma frozen at -70°C. PRA was assayed from the generation of Ang I (42).
Statistical analysis
Data are presented as mean ± standard error (SEM). Within each series, data were analyzed at each time point for changes in MAP relative to baseline using analysis of variance (ANOVA) for repeat observations. Where appropriate, a post-hoc Dunnett's t test was used to assess differences from vehicle between groups. Statistical significance is taken at p < 0.05.
Results
Data are shown in figure 1 for sham operated control and 2K,1C rats 2-3 weeks after clipping. Compared to controls, anesthetized 2K,1C rats had significant elevations of MAP that averaged +35 mmHg and 2-fold elevations of PRA and plasma MDA. TxB 2 excretion by conscious 2K,1C rats during a 24 hour urine collection from both kidneys also was increased two-fold. One limitation is that rats were studied under anesthesia. However prior studies in conscious 2K,1C rats studied 3 weeks after clipping have shown similar increases in BP and PRA and similar reductions in MAP with AT 1 -R or TP-R antagonists (43) . A second limitation is that urine was collected from the clipped and non-clipped kidneys together. However, enhanced II-infused rats (25, 47, 48) and in the early 2K,1C model in this, and a previous study (43) . We now find that a COX-1 antagonist, given acutely to anesthetized 2K,1C rats, reduces their BP and TxB 2 generation in the post-clip kidney whereas a COX-2 antagonist does not reduce the BP and actually increases renal TxB 2 generation. The fall in MAP in response to the COX-1 antagonist of 28±7 mmHg was quite similar to the fall of 22±3 mmHg in response to the TP receptor antagonist or of 36±5 mmHg in response to the ACEI which was also shown to reduce renal TxB 2 excretion. These results are consistent with the reduction in TxB 2 excretion reported in the COX-1 knockout mouse (16) and the increase in TxB 2 excretion reported after COX-2 inhibition (27) and confirm that the doses of these COX antagonists were effective at the time that the measurements of MAP were made. Since the antihypertensive response to blockade of COX-1 and TP receptors were quite similar in this study, it is not likely that isoprostanes (which 
